Authors state moderate‐certainty evidence from this review also indicates no differences between the drugs in terms of time to seizure recurrence and seizure remission. Authors highlight however, the trials contributing to the analyses had methodological inadequacies and methodological design differences that may have impacted upon the results of this review. Therefore, they do not suggest that results of this review alone should form the basis of a treatment choice for a patient with newly onset seizures.